JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2017, Vol. 55 ›› Issue (5): 91-94.doi: 10.6040/j.issn.1671-7554.0.2017.071
Previous Articles Next Articles
LI Yanxiang, ZHANG Wenhua, YANG Feilong, FANG Liang, XU Zhonghua
CLC Number:
| [1] 韩苏军, 张思维, 陈万青, 等. 中国膀胱癌发病现状及流行趋势分析[J]. 癌症进展, 2013, 11(1): 89-95. [2] Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90. [3] 周利群, 李学松, 熊耕砚. 中国人群尿路上皮癌新进展[J]. 北京大学学报(医学版), 2014, 46(4): 504-506. [4] Tomlinson GE, Chen TT, Stastny VA, et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier[J]. Cancer Res, 1998, 58(15): 3237-3242. [5] Jhanwar-Uniyal M. BRCA1 in cancer cell, cycle and genomic stability[J]. Front Biosci, 2003, 8(9): 1107-1117. [6] Seery LT, Knowlden JM, Gee JM, et al. BRCA1 expression levels predict distant metastasis of sporadic breast cancers[J]. Int J Cancer, 1999, 84(3): 258-262. [7] Joerger M, deJong D, Burylo A, et al. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy[J]. Lung Cancer, 2011, 74(2): 310-317. [8] Wang L, Wei J, Qian X, et al. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and /or docetaxe[J]. BMC Cancer, 2008, 8(1): 197. [9] Neveling K, Kalb R, Florl AR, et al. Disruption of the FA/BRCA pathway in bladder cancer[J]. Cytogenet Genome Res, 2007, 118(2-4): 166-176. [10] Font A, Taron M, Gago JL, et al. BRCAl mRNA expression and outcome to neoadjuvant cisplatin-based chemothorapy in baadder cancer[J]. Ann Oncol, 2011, 22(1): 139-144. [11] 那彦群, 孙光. 中国泌尿外科疾病诊断治疗指南[M]. 北京: 人民卫生出版社, 2011: 32. [12] Cheung G, Sahai A, Billia M, et al. Recent advances in the diagnosis and treatment of bladder cancer[J]. BMC Med, 2013, 11: 13. [13] Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer[J]. Lancet Oncol, 2003, 4(8): 489-497. [14] 徐光辉, 李玉, 叶胜龙, 等. 结直肠癌组织中ERCC1和BRCA1的表达及其与铂类化疗疗效的相关性[J]. 复旦学报(医学版), 2011, 38(4): 352-323. XU Guanghui, LI Yu, YE Shenglong, et al. ERCC1 and BRCA1 expressions in the tissues of colorectal cancer and its relationship with clinical significance of platinum-based chemotherapy[J]. Fudan University Journal of Medical Sciences, 2011, 38(4): 352-323. [15] 谷海燕, 项锋钢, 信芳杰, 等. NSCLC含铂新辅助化疗后ERCC1和BRCA1表达及与疗效关系[J].齐鲁医学杂志, 2012, 27(2): 98-100. GU Haiyan, XIANG Fenggang, XIN Fangjie, et al. Expressionsof erccland brcaland their relationship with curative effect in non-small cell lung cancer after platinum-based neoadjuvant chemo therapy[J]. Medical Journal of Qilu, 2012, 27(2): 98-100. [16] Kennedy RD, Quinn JE, Johnston PG, et al. BRCA1: mechanisms of inactivation and implications for management of patients[J]. Lancet, 2002, 360(9338): 1007-1014. [17] Raj GV, Karavadia S, Schlomer B, et al. Conmporary use of perioperative cisplatin-based chemotherapy in patients with muscle invasive bladder cancer[J] , Cancer, 2011, 117(2): 276-282. [18] Fedeli U, Fedewa SA, Ward EM, et al. Treatment of muscle invasive bladder cancer evidence from the National Cancer Database, 2003 to 2007[J]. J Urol, 2011, 185(1): 72-78. [19] Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis[J]. Cancer Res, 2003, 63(19): 6221-6228. [20] Wang B, Matsuoka S, Ballif BA, et al. Abmxas and RAP80 form a BRCAI protein complex required for the DNA damage response[J]. Science, 2007, 316(5828): 1194-1198. [21] Lotti LV, Ottini L, D'Amico C, et al. Subcellular localization of the BRCA1 gene product in mitotic cells[J]. Genes Chromosomes Cancer, 2002, 35(3): 193-203. [22] Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers[J]. Nat Rev Cancer, 2004, 4(10): 814-819. [23] Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression[J]. PLoS One, 2009, 4(5): 5133. [24] Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors[J]. J Natl Cancer Inst, 2000, 92(7): 564-569. [25] Taron M, Rosell R, Felip E, et al. BRCAl mRNA expression levels as an indicator of chemoresistance in lung cancer[J]. Hum Mol Genet, 2004, 13(20): 2443-2449. [26] Lafarge S, Sylvain V, Ferrara M, et al. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway[J]. Oncogene, 2001, 20(45): 6597-6606. [27] Gallagher DJ,Konner JA, Bell-McGuinn KM, et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinumsensitivity[J]. Ann Oncol, 2011, 22(5): 1127-1132. [28] Tassone P, Di Martino MT, Ventura M, et al. Loss of BRCAl function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo[J].Cancer Biol Ther, 2009, 8(7): 648-653. |
| No related articles found! |
|
||
